A Phase 2 interventional study of Pregabalin in Epilepsy, Partial, sponsored by Pfizer. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-01-01.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.
Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 13th largest by enrollment, is the only one that started in 1997, is the only one in phase 2, and was the 1st registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 4
First in 1997; this study’s year is marked. 1 started in 1997.
This study's enrollment of 82 is close to the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 244 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing pregabalin in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Safety
The record gives a start of Nov 1997 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin